News

More Japanese drug OKs: GSK’s Rotarix and Lamictal; Takeda’s Liovel and new use for Eisai/Abbott’s Humira

04-07-2011

In a flurry of Japanese drug approvals over the last few days (see also The Pharma Letters July 1 and…

Abbott LaboratoriesAnti-Arthritics/RheumaticsAsia-PacificDiabetesEisaiGlaxoSmithKlineHumiraLamictalLiovelNeurologicalPharmaceuticalRegulationRotarixTakeda PharmaceuticalsVaccines

US FDA moves approval goalposts for GSK/Valeant’s ezogabine and Eisai’s eribulin; Abbott/Eisai’s Humira filed for additional indication in Japan

01-09-2010

The US Food and Drug Administration disappointed several companies yesterday by moving the goalposts…

Abbott LaboratoriesAnti-Arthritics/RheumaticsAsia-PacificEisaieribulinezogabineGlaxoSmithKlineHumiraNeurologicalNorth AmericaOncologyPharmaceuticalPotigaRegulationValeant Pharmaceuticals

Insight on how rheumatologists are utilizing biologics in RA treatment

16-12-2009

BioTrends Research Group has released ChartTrends: Biologics in Rheumatoid Arthritis, a syndicated publication…

AbataceptAbbott LaboratoriesadalimumabAlphaAmgenAnti-Arthritics/RheumaticsArzerraBiotechnologyCertolizumab PegolCimziaEnbreletanerceptGenentechGeneralGlaxoSmithKlineGSKHealthcareHumirainfliximabmethotrexateOfatumumab InjectionOrenciaPfizerPharmaceuticalProlastinRemicadeRituxanrituximabRocheTrexallUCBWyeth

COMPANY SPOTLIGHT

Menarini

Back to top